BT-8009 is under clinical development by Bicycle Therapeutics and currently in Phase II for Metastatic Transitional (Urothelial) Tract Cancer. According to GlobalData, Phase II drugs for Metastatic Transitional (Urothelial) Tract Cancer have a 47% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how BT-8009’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BT-8009 is under development for the treatment of solid tumors like metastatic urothelial (transitional cell) carcinoma, non-small cell lung cancer, esophageal cancer, bladder cancer, urothelial carcinoma, pancreatic cancer, gastric cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, head and neck cancer and triple negative breast cancer. The drug candidate is a bicyclic peptide conjugate being developed based on bicyclic peptide technology composed of bicyclic peptides in combination with a matrix of different linkers for the delivery of a cytotoxic payload to the tumor cells. The peptide acts by targeting cells expressing nectin-4. It is administered through intravenous route.
Bicycle Therapeutics overview
Bicycle Therapeutics is a biotechnology company. It develops bicyclic peptides Medicines for the treatment of cancers and other debilitating diseases. The company’s Bicycle conjugates include BT1718, BT5528, and BT8009; and Immuno-Oncology offers BT7480, BT7401, and BT7455. Bicycle Therapeutics proprietary bicyclic peptide technology enables systematic cyclisation of peptides and helps to identify bicycles that provide antibody-like affinity and selectivity in a much smaller chemically synthesized molecule. The company operates with other biotechnology companies for the development of bicyclic peptide inhibitors for the treatment of ophthalmic diseases such as diabetic macular edema, renal elimination, versatility for multimerization and conjugation. It works in collaboration with Cancer Research UK(CRUK), AstraZeneca Plc in the areas of oncology, respiratory, cardiovascular, and metabolic diseases, among others. The company has operations in Massachusetts, the US. Bicycle Therapeutics is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of BT-8009’s drug-specific PTSR and LoA scores, buy the report here.